Compare LCUT & ENLV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LCUT | ENLV |
|---|---|---|
| Founded | 1945 | 2005 |
| Country | United States | Israel |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 201.8M | 196.2M |
| IPO Year | 1996 | 2014 |
| Metric | LCUT | ENLV |
|---|---|---|
| Price | $8.88 | $0.72 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 1 | 2 |
| Target Price | $5.00 | ★ $20.00 |
| AVG Volume (30 Days) | 180.7K | ★ 418.0K |
| Earning Date | 05-07-2026 | 05-29-2026 |
| Dividend Yield | ★ 2.54% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $647,933,000.00 | N/A |
| Revenue This Year | $3.74 | N/A |
| Revenue Next Year | $1.20 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $2.90 | $0.66 |
| 52 Week High | $9.80 | $2.10 |
| Indicator | LCUT | ENLV |
|---|---|---|
| Relative Strength Index (RSI) | 58.69 | 39.84 |
| Support Level | $3.44 | $0.66 |
| Resistance Level | $9.80 | $1.23 |
| Average True Range (ATR) | 0.81 | 0.06 |
| MACD | 0.04 | 0.01 |
| Stochastic Oscillator | 65.23 | 20.89 |
Lifetime Brands Inc is a U.S.-based company that designs, sources, and sells branded kitchenware, tableware, and other home solution products used in the home. The company's product portfolio comprises kitchen tools, cutlery, thermometers, cutting boards, spice racks, dinnerware, stemware, flatware, bath scales, thermal beverage ware, food storage, neoprene travel products, etc. These products are marketed under owned or licensed brands like Farberware, KitchenAid, Mikasa, Misto, Taylor, Sabatier, and Pfaltzgraff, among others. The company mainly sells its products directly to retailers and distributors, and a limited selection directly to consumers through its own websites. It has two reportable operating segments: U.S., which derives maximum revenue, and International.
Enlivex Ltd is a clinical stage macrophage reprogramming immunotherapy company currently focused on the late-stage clinical development of Allocetra, a novel therapy designed to treat the joint disease osteoarthritis. Additionally, it has developed a treasury using the RAIN protocol, which currently serves as the primary treasury reserve asset of the company.